Allogene Therapeutics
Suhasni Gopalakrishnan has extensive experience in the biopharmaceutical industry and research institutions. Currently serving as Director and previously as Associate Director and Principal Scientist at Allogene Therapeutics, Suhasni has a solid background in leadership and scientific research. Prior roles include Senior Scientist at Pfizer and Postdoctoral Research Associate at the University of Southern California, focusing on stem cell and regenerative medicine. Additionally, Suhasni was a Postdoctoral Fellow at Washington University School of Medicine in St. Louis, specializing in pathology and immunology.
This person is not in the org chart
This person is not in any teams
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.